Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 49 of 157 for:    Idiopathic Dilated Cardiomyopathy

Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02292043
Recruitment Status : Unknown
Verified November 2014 by Wei Liu, Harbin Medical University.
Recruitment status was:  Recruiting
First Posted : November 17, 2014
Last Update Posted : November 17, 2014
Sponsor:
Information provided by (Responsible Party):
Wei Liu, Harbin Medical University

Brief Summary:
The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction.

Condition or disease Intervention/treatment
Congestive Heart Failure Drug: HTEA

Detailed Description:
The investigators would evaluate the effects of the novel method, HTEA on cardiac function in the heart failure patients secondary to idiopathic dilated cardiomyopathy and post-myocardial infarction. The specific index is 6 miniutes walk distance, echocardiography, NYHA, NTproBNP level, peripherial WBC, RBC, PLT, Cre, UA, K+, Na+ upon entrance to hospital and 4 weeks after HTEA treatment, and 3 months after discharge. The morbidity and re-hospitalization would also calculated 3 months after discharge.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction
Study Start Date : May 2013
Estimated Primary Completion Date : January 2015
Estimated Study Completion Date : January 2015


Group/Cohort Intervention/treatment
idiopathic dilated cardiomyopathy group
idiopathic dilated cardiomyopathy group treated with HTEA
Drug: HTEA
HTEA

post-myocardial infarction group
post-myocardial infarction group treated with TEA
Drug: HTEA
HTEA




Primary Outcome Measures :
  1. Morbidity [ Time Frame: 1 months to 3 months after discharge ]

Secondary Outcome Measures :
  1. The decreased degree of NT-proBNP higher than 30% [ Time Frame: 3 months after discharge ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
heart failure.
Criteria

Inclusion Criteria:

  • 90 chronic cardiac failure patients in our hospital were selected and divided into two groups.

Exclusion Criteria:

  • Vavular diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02292043


Contacts
Layout table for location contacts
Contact: wei liu, Ph.D. 86-18904502999
Contact: xiaohui ren 86-451-85552320

Locations
Layout table for location information
China, Heilongjiang
Ren Xiaohui Recruiting
Harbin, Heilongjiang, China, 150001
Contact: Xiaohui Ren    86-85552320    renxiaohui2004@163.com   
the first affiliated hospital of Harbin Medical University Recruiting
Harbin, Heilongjiang, China, 150001
Contact: Xiaohui Ren    86-451-85552320      
Sponsors and Collaborators
Harbin Medical University
Investigators
Layout table for investigator information
Principal Investigator: wei liu First Affiliated Hospital of Harbin Medical University

Layout table for additonal information
Responsible Party: Wei Liu, Prof. Liu, Harbin Medical University
ClinicalTrials.gov Identifier: NCT02292043     History of Changes
Other Study ID Numbers: wei liu
First Posted: November 17, 2014    Key Record Dates
Last Update Posted: November 17, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Cardiomyopathy, Dilated
Heart Failure
Myocardial Infarction
Infarction
Heart Diseases
Cardiovascular Diseases
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Vascular Diseases
Cardiomegaly